Background/Objectives: Few large cohorts with relatively uniform treatment approaches and long-term follow-up are available for assessing clinical outcomes for breast cancer (BC) patients. The Institut Català d’Oncologia (ICO) Breast Cancer Cohort was designed to well characterize treatment patterns and overall survival outcomes at 5 and 10 years, with a particular focus on patients < 40 and ≥70 years old, age groups often underrepresented in clinical trials.Methods: In this retrospective, observational study, we included all pathologically confirmed invasive BC patients diagnosed and treated between 2010 and 2014 at ICO, a Spanish reference cancer center, with a follow-up until November 2023. We collected comprehensive real-world data on clinicopathologic characteristics and treatment modalities. Overall survival (OS) was estimated using the Kaplan–Meier technique and was reported stratified by prognostic factors for the age groups of ≤40, 41–69 and ≥70. The Multivariate Cox model was used to estimate the risk of death for subgroups of age, adjusting for subtype, stage and grade.Results: Overall, 3451 patients with stage I to IV BC were diagnosed and treated, with a mean age of 58 years (range 19–98); 371 (10.8%) were diagnosed ≤40 years, and 756 (21.9%) were ≥70 years. With a mean follow-up of 9.9 years (SD = 3.5), the 5- and 10-year OS were 89% (95% CI: 86–92%) and 85% (95% CI: 81–88%) for patients ≤ 40, respectively; for those aged 41–69 years, 91% (95% CI: 90–92%) and 85% (95% CI: 83–86%), respectively; and 70% (95% CI: 66–73%) and 50% (95% CI: 47–54%) for those ≥70 years, respectively. The 5- and 10-year relative survival (RS) were 92% and 88% for patients < 70 years, respectively, and 82% and 77% for those ≥70 years, respectively. The Multivariate Cox model identified a HR of 4.90 (95% CI: 3.44–6.97,p< 0.001) for patients ≥ 70 years compared to those between 41 and 69 years.Conclusions: The ICO Breast Cancer Cohort, as far as we know, the largest in Spain with long-term follow-up, underscores the critical role of age and subtype in determining overall survival outcomes in patients with breast cancer.
背景/目的：目前可用于评估乳腺癌患者临床结局的、治疗方法相对统一且具有长期随访数据的大型队列研究较少。加泰罗尼亚肿瘤研究所乳腺癌队列旨在详细描述治疗模式及5年和10年总生存结局，尤其关注年龄<40岁和≥70岁的患者群体，这些年龄组在临床试验中通常代表性不足。 方法：在这项回顾性观察研究中，我们纳入了2010年至2014年间在西班牙癌症参考中心——加泰罗尼亚肿瘤研究所诊断并治疗的所有经病理证实的浸润性乳腺癌患者，随访至2023年11月。我们收集了关于临床病理特征和治疗模式的全面真实世界数据。采用Kaplan-Meier法评估总生存期，并按年龄组（≤40岁、41-69岁和≥70岁）的预后因素进行分层报告。使用多变量Cox模型评估各年龄亚组的死亡风险，并对亚型、分期和分级进行调整。 结果：总体而言，共有3451例I至IV期乳腺癌患者被诊断和治疗，平均年龄58岁（范围19-98岁）；其中371例（10.8%）诊断时年龄≤40岁，756例（21.9%）≥70岁。平均随访9.9年（标准差=3.5），≤40岁患者的5年和10年总生存率分别为89%（95% CI：86-92%）和85%（95% CI：81-88%）；41-69岁患者分别为91%（95% CI：90-92%）和85%（95% CI：83-86%）；≥70岁患者分别为70%（95% CI：66-73%）和50%（95% CI：47-54%）。<70岁患者的5年和10年相对生存率分别为92%和88%，≥70岁患者分别为82%和77%。多变量Cox模型显示，与41-69岁患者相比，≥70岁患者的死亡风险比为4.90（95% CI：3.44-6.97，p<0.001）。 结论：据我们所知，加泰罗尼亚肿瘤研究所乳腺癌队列是西班牙规模最大且具有长期随访数据的队列，其研究结果强调了年龄和亚型在决定乳腺癌患者总生存结局中的关键作用。
肿瘤(癌症)患者之家